Update
$Brainstorm Cell Therapeutics(BCLI.US$ BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo. Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action and complement clinical effects observed in ALS.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
sendhelp : did you enter?
TrytosaveabitOP sendhelp: Was already in! One of my swings! GL
Greatvaluetrader1738 : and it crashes
TrytosaveabitOP Greatvaluetrader1738: 90% of market is crashing
Greatvaluetrader1738 : true.
Greatvaluetrader1738 : let's test 1.00 again
TrytosaveabitOP Greatvaluetrader1738: Would be nice! GL
Double_Bottom :